Singh Biotech LLP

Dear Friends, We are Happy to share Our Founder Manoj Kumar Singh has been confirmed as a Nominee for The Campus Connect -REX Karmaveer Global Young Leaders Fellowship ( ) and Karmaveer Chakra Awards 2019 instituted by in partnership with the .

Keep Supporting And Blessing Me. Being A Hemophiliac It Is A Recognition For Our Potential To Bring A Change In Society And That We Can Do Anything. 🙏🙏

celebrates young from colleges globally, who make a difference in our society with their to be the change and REXChange mindsets by walking the path less trodden. The award to honour individual work done by people to "be the change" and/or walk off beat road or any field of work that inspires and brings in Growth mindset.
The Campus Connect REX - Ideas for Action

Now Bye Bye To Lab Technicians..

An augmented reality microscope with real-time artificial intelligence integration for cancer diagnosis An artificial intelligence-powered microscope able to detect tumor cells in histopathology slides holds promise for accelerating pathology workflows for cancer diagnosis

Our founder gets featured as Rare Warrior And His Life Story In Brief... Lets All Get Inspired... Please Like and Share The Video
https://youtu.be/Cm6v57KqsZo

Severe Hemophilia Se Ladta Hua Rare Warrior Manoj Kumar Singh|Hemophilia| Causes |Symptoms|Diagnosis Humara Iss Episode Ke Rare Warrior Manoj Kumar Singh Hain. Wo Ek Rare Bleeding Disorder Hemophilia, Jise Royal Disease Bhi Kehte Hain Se Lad Rahe Hain. Hemop...

Now Indian Universities Can Also Carry out Research On People.. But need to follow ICMR guidelines...

India’s clinical-trial rules to speed up drug approvals Drugs that have been approved in other some countries will no longer require trials in India.

Lilly price break reverses NICE’s 'No' ruling on breast cancer drug Verzenio..Read On...http://bit.ly/2Doo7U9

#

Lilly price break reverses NICE’s 'No' ruling on breast cancer drug Verzenio | FiercePharma England’s drug-cost watchdogs initially told Eli Lilly that its CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn't cost-effective compared to rivals from Pfizer and Novartis. So Lilly dished up a new price break—and now NICE is on board.

Study: 1 in 4 antibiotic prescriptions likely inappropriate..Read On...http://bit.ly/2W5tBu4

Study: 1 in 4 antibiotic prescriptions likely inappropriate | FierceHealthcare A new study mapping ICD-10 diagnostic codes to antibiotic prescriptions found that almost a quarter of prescriptions were likely inappropriate for the conditions noted. And that’s probably a conservative estimate.

Spectrum empties marketed portfolio worth $300M to deal-hungry Aurobindo..Read On...http://bit.ly/2sBr2mf

Spectrum empties marketed portfolio worth $300M to deal-hungry Aurobindo | FiercePharma Buzz of a potential sale at Spectrum Pharma first emerged last June. As it turns out, the rare disease and cancer specialist is indeed pulling off a transaction—but only for its FDA-approved products. The buyer, Aurobindo, has been busy shopping lately.

Apple, J&J to put the Apple Watch’s ECG through large-scale clinical testing..Read On...http://bit.ly/2W3X0oC

Apple, J&J to put the Apple Watch’s ECG through large-scale clinical testing | FierceBiotech Apple and Johnson & Johnson are teaming up on a multiyear research study to see if the latest Apple Watch can help catch and diagnose elderly people with atrial fibrillation earlier and faster than before.

Novartis allies with Oxford academics for big data R&D drive..Read On...http://bit.ly/2T5cRBg

Novartis allies with Oxford academics for big data R&D drive | FierceBiotech Novartis has teamed up with the University of Oxford to use artificial intelligence to improve drug development. The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials to better understand diseases important to Novartis’ prospects.

Celgene strikes Obsidian deal to boost CAR-T options..Read On...http://bit.ly/2FzqpBW

Celgene strikes Obsidian deal to boost CAR-T options | FierceBiotech Celgene is pushing ahead with its immuno-oncology dealmaking program while working toward its $74 billion takeout by Bristol-Myers Squibb. The big biotech ended the week by expanding its CAR-T toolkit via a deal with Obsidian Therapeutics and placing an $80 million bet on Kyn Therapeutics.

FDA panel split on Sanofi's Type 1 diabetes hopeful Zynquista..Read On..http://bit.ly/2CvsY48

FDA panel split on Sanofi's Type 1 diabetes hopeful Zynquista | FiercePharma Should the FDA approve Sanofi’s SGLT2 candidate for patients with Type 1 diabetes? Turns out, the experts couldn't agree. An agency advisory panel voted 8-8 on the potential nod, and the FDA's eventual decision is anybody's guess.

Singh Biotech LLP Wishes Every Indian Across The Globe A Very Happy Republic Day..!